Privia Health’s stock lags with a modest 3.6% gain in 2026, hindered by limited distribution, weak cash flow margins, and zero ROIC—making it a tough play in a crowded, regulated space. With a pricey P/E of 23.6, investors are looking elsewhere, especially toward high-growth software stocks that deliver stronger returns and smarter capital use.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
